Experiment 66940
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | MARCELLO,S: GLADSTEIN,J: TESONE,P: MAS,R:. (2000). EFFECTS OF BENZAFIBRATE PLUS POLICOSANOL OR PLACEBO IN PATIENTS WITH COMBINED DYSLIPIDEMIA: A PIOLT STUDY.. 61(6) |
| Amount utilized | |
| Compound isolated | |
| Disease | A RANDOMIZED, DOUBLE-BLIND, CLINICAL PILOT STUDY WAS TO COMPARE THE EFFICACY AND TOLERABILITY OF THE COMBINATION THERAPY BEZAFIBRATE PLUS POLICOSANOL VERUS BEZAFIBRATE PLUS PLACEBO IN PATIENTS WITH COMBINED DSYLIPIDEMIA. AFTER 6 WEEKS OF A STANDARD LIPID-LOWERING DIET, 29 PATIENTS WERE ASSIGNED RANDOMLY TO RECEIVE, UNDER DOUBLE-BLIND CONDITIONS, BEZAFIBRATE 400 MG/D PLUS POLICOSANOL 10 MG/D OR BEZAFIBRATE 400 MG/D PLUS PLACEBO. TREATMENTS WERE TAKEN ONCE DAILY WITH THE EVENING MEAL FOR 8 WEEKS. BENZAFIBRATE PLUS POLICOSANOL SIGNIFICANTLY REDUCED LEVELS OF TOTAL CHOLESTEROL (TC) LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TRIGLYCERIDES AND THE ATHEROGENIC RATIOS OF LDL-C TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TC TO HDL-C. LEVELS OF HDL-C INCREASED SIGNIFICANTLY IN BOTH GROUPS. |
| Dose amount | 10.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |